Skip to main content

Drug Interactions between ipratropium and Trelegy Ellipta

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ipratropium umeclidinium

Applies to: ipratropium and Trelegy Ellipta (fluticasone / umeclidinium / vilanterol)

Using ipratropium together with umeclidinium may increase side effects such as drowsiness, blurred vision, dry mouth, heat intolerance, flushing, decreased sweating, difficulty urinating, abdominal cramping, constipation, rapid heart beat, confusion, memory problems, and glaucoma. Although serious side effects are not very common with inhaled or topically applied preparations because only limited amounts of the medication generally get absorbed into the bloodstream from the lungs or skin, they can sometimes occur, especially in the elderly or when combined with other medications that have similar side effects. Talk to your doctor if you have any questions or concerns. Your doctor may be able to prescribe alternatives that do not interact. You should avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how these medications affect you. When using an inhaled product by nebulizer, keep your eyes closed or use an eye mask to avoid having the medication get into the eyes, which can cause blurry vision and eye pain as well as increase absorption of the medication into the bloodstream. When using a topical preparation such as a cream or solution, avoid applying to broken skin or using occlusive dressings over the application areas, and also avoid touching the eyes until after you wash your hands with soap and water. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Switch to professional interaction data

Minor

fluticasone vilanterol

Applies to: Trelegy Ellipta (fluticasone / umeclidinium / vilanterol) and Trelegy Ellipta (fluticasone / umeclidinium / vilanterol)

Information for this minor interaction is available on the professional version.

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Anticholinergics/antispasmodics

Therapeutic duplication

The recommended maximum number of medicines in the 'anticholinergics/antispasmodics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'anticholinergics/antispasmodics' category:

  • ipratropium
  • Trelegy Ellipta (fluticasone/umeclidinium/vilanterol)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.